(NASDAQ: EXAS) Exact Sciences's forecast annual revenue growth rate of 12.57% is forecast to beat the US Diagnostics & Research industry's average forecast revenue growth rate of 5.91%, and it is also forecast to beat the US market's average forecast revenue growth rate of 8.88%.
Exact Sciences's revenue in 2024 is $2,534,840,000.On average, 7 Wall Street analysts forecast EXAS's revenue for 2024 to be $522,628,950,940, with the lowest EXAS revenue forecast at $520,798,231,578, and the highest EXAS revenue forecast at $523,990,595,752. On average, 7 Wall Street analysts forecast EXAS's revenue for 2025 to be $593,144,400,404, with the lowest EXAS revenue forecast at $587,653,349,497, and the highest EXAS revenue forecast at $598,484,321,471.
In 2026, EXAS is forecast to generate $662,000,374,088 in revenue, with the lowest revenue forecast at $656,981,165,676 and the highest revenue forecast at $667,019,582,499.